News for Moderna, Inc. (0A45.L)

Moderna (MRNA) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has endorsed the approval of a newly fo

Long-established in the Biotechnology industry, Moderna Inc (MRNA) has enjoyed a stellar reputation. It has recently witnessed a daily gain of 7.21%, juxtaposed

On July 22, 2025, analyst Dimple Gosai from B of A Securities released an updated report on Moderna (MRNA), maintaining the current "Underperform" rating. The r

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Key Takeaways: Moderna halts plans for an mRNA manufacturing facility in Japan due to a challenging business climate. Wall Street analysts provide a mixe

Long-established in the Biotechnology industry, Moderna Inc (MRNA) has enjoyed a stellar reputation. However, it has recently witnessed a daily loss of 1.65%, j

Moderna is expected to announce its second-quarter results in the upcoming month, and analysts expect a slight reduction in its losses.

Moderna (MRNA) experienced a notable upswing in its stock price, climbing by $1.29 or 3.95%, to approximately $34.09. The trading session revealed reduced optio

Key Takeaways: The FDA approval expands Moderna's Spikevax usage to children over six months old. Analysts predict a significant price movement for Moder

Shares of Moderna (MRNA) experienced a modest rise, gaining $0.29, or 0.89%, reaching approximately $32.83. The stock saw a significant surge in options trading

Long-established in the Biotechnology industry, Moderna Inc (MRNA) has enjoyed a stellar reputation. However, it has recently witnessed a daily loss of 1.41%, j

Key Takeaways: Moderna (MRNA) experiences notable growth, with its stock price surging by 10.71% amid strong performance in the S&P 500 Health Care Index.

Key Highlights: FDA restricts Moderna's COVID-19 vaccine use, impacting target demographics. Wall Street analysts show a mixed outlook with varied price

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Shares of Moderna (MRNA) saw a rise of 71 cents, or 2.64%, reaching approximately $27.57. This price movement coincided with a significant surge in options trad

Shares of Moderna (MRNA) have experienced a slight uptick, rising by $0.22 or 0.88%, to approximately $25.77. The stock saw a significant surge in options tradi

Caris Life Sciences, an AI-driven precision oncology company, is targeting a $5.35 billion valuation in its U.S. initial public offering, aiming to raise up to $423.5 million. The Irving, Texas-based firm, backed by investment giants Sixth Street and Neuberger Berman, has already conducted 6.5 million molecular tests across 849,000 patient cases, establishing partnerships with over 100 biopharmaceutical firms, including Moderna Inc (NASDAQ:MRNA) and AbbVie (NYSE:ABBV), according to its prospectu

Shares of Moderna (MRNA) saw a slight dip, falling 20 cents to approximately $25.80 amid a bearish outlook from option traders. The trading activity was relativ

Moderna, Inc. (NASDAQ:MRNA) Barclays Speaking the Science Call Series Call June 16, 2025 10:00 AM ETCompany ParticipantsLavina Talukdar - Senior VP &...